{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:49:09Z","timestamp":1792162149106,"version":"4.4.0"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Malaria remains a global health burden, requiring optimised antimalarial therapies. This review examines the role of\n                    <jats:italic>CYP450 3A<\/jats:italic>\n                    family and\n                    <jats:italic>2D6<\/jats:italic>\n                    alleles in antimalarial drug metabolism, highlighting pharmacogenetics and distribution across populations. A narrative literature review was conducted using a structured literature search of PubMed, Web of Science, and Google Scholar to evaluate how\n                    <jats:italic>CYP3A<\/jats:italic>\n                    and\n                    <jats:italic>CYP2D6<\/jats:italic>\n                    alleles affect the metabolism of quinine, artemether-lumefantrine, primaquine and tafenoquine. The review analysed genetic variations and interactions with other drugs.\n                    <jats:italic>CYP3A<\/jats:italic>\n                    alleles influence quinine metabolism, with normally functioning alleles (\n                    <jats:italic>CYP3A4*1<\/jats:italic>\n                    or\n                    <jats:italic>CYP3A5*1<\/jats:italic>\n                    ) associated with higher metabolism rates, while decreased- or non-functional alleles (\n                    <jats:italic>CYP3A4*1B<\/jats:italic>\n                    or\n                    <jats:italic>CYP3A5*3, *6, *7<\/jats:italic>\n                    ) are associated with reduced metabolism. The impact of\n                    <jats:italic>CYP3A<\/jats:italic>\n                    alleles on artemether-lumefantrine metabolism is less clear but may be relevant in pregnancy, individuals with HIV receiving efavirenz, and individuals with tuberculosis receiving rifampicin.\n                    <jats:italic>CYP2D6<\/jats:italic>\n                    alleles associated with poor or intermediate metaboliser phenotypes may contribute to primaquine treatment failure, while interactions with drugs like chloroquine or dihydroartemisinin-piperaquine may elevate primaquine plasma concentrations. Tafenoquine could represent a potential alternative in individuals with reduced CYP2D6 activity, as current human studies have not shown an increased relapse risk, although clinical evidence remains limited. Understanding these genetic differences could help explain variability in antimalarial drug exposure and treatment response across diverse malaria-endemic populations. Genotyping may help explain variability in drug exposure or treatment response in selected clinical settings. Pharmacogenetic insights may therefore support safer and more effective antimalarial therapies worldwide.\n                  <\/jats:p>","DOI":"10.1186\/s12936-026-06181-8","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:01:55Z","timestamp":1792155715000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CYP3A and CYP2D6 variability in antimalarial pharmacokinetics and pharmacogenetics across populations: a narrative review"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5683-5705","authenticated-orcid":false,"given":"Ursula","family":"Benz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Junnila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter C.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Schlagenhauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Rothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"1","key":"6181_CR1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00002018-200427010-00003","volume":"27","author":"WR Taylor","year":"2004","unstructured":"Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf. 2004;27(1):25\u201361.","journal-title":"Drug Saf"},{"issue":"6","key":"6181_CR2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000109767","volume":"53","author":"HO AlKadi","year":"2007","unstructured":"AlKadi HO. Antimalarial drug toxicity: a review. Chemother. 2007;53(6):385\u201391.","journal-title":"Chemother"},{"issue":"5","key":"6181_CR3","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s13318-016-0399-1","volume":"42","author":"H Elewa","year":"2017","unstructured":"Elewa H, Wilby KJ. A review of pharmacogenetics of antimalarials and associated clinical implications. Eur J Drug Metab Pharmacokinet. 2017;42(5):745\u201356.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"6181_CR4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ijid.2020.12.009","volume":"104","author":"SR Pallerla","year":"2021","unstructured":"Pallerla SR, Elion Assiana DO, Linh LTK, Cho FN, Meyer CG, Fagbemi KA, et al. Pharmacogenetic considerations in the treatment of co-infections with HIV\/AIDS, tuberculosis and malaria in Congolese populations of Central Africa. Int J Infect Dis. 2021;104:207\u201313.","journal-title":"Int J Infect Dis"},{"issue":"2","key":"6181_CR5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2217\/pme-2019-0110","volume":"17","author":"F Radouani","year":"2020","unstructured":"Radouani F, Zass L, Hamdi Y, Rocha JD, Sallam R, Abdelhak S, et al. A review of clinical pharmacogenetics studies in African populations. Per Med. 2020;17(2):155\u201370.","journal-title":"Per Med"},{"issue":"4","key":"6181_CR6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043383","volume":"24","author":"CR Chamboko","year":"2023","unstructured":"Chamboko CR, Veldman W, Tata RB, Schoeberl B, Tastan Bishop \u00d6. Human cytochrome P450 1, 2, 3 families as pharmacogenes with emphases on their antimalarial and antituberculosis drugs and prevalent African alleles. Int J Mol Sci. 2023;24(4):3383.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"6181_CR7","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4269\/ajtmh.15-0565","volume":"94","author":"RJ Stoney","year":"2016","unstructured":"Stoney RJ, Chen LH, Jentes ES, Wilson ME, Han PV, Benoit CM, et al. Malaria prevention strategies: adherence among Boston area travelers visiting malaria-endemic countries. Am J Trop Med Hyg. 2016;94(1):136\u201342.","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"6181_CR8","first-page":"71","volume":"30","author":"G Bocci","year":"2018","unstructured":"Bocci G, Troiano G, Golinelli D, Verzuri A, Rossi S, Nante N. Malaria chemoprophylaxis\u2019 compliance in travelers. Ann Ig. 2018;30(1):71\u20132.","journal-title":"Ann Ig"},{"issue":"4","key":"6181_CR9","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaa292","volume":"22","author":"R Hassan","year":"2021","unstructured":"Hassan R, Allali I, Agamah FE, Elsheikh SSM, Thomford NE, Dandara C, et al. Drug response in association with pharmacogenomics and pharmacomicrobiomics: towards a better personalized medicine. Brief Bioinform. 2021;22(4):bbaa292.","journal-title":"Brief Bioinform"},{"key":"6181_CR10","first-page":"449","volume":"16","author":"KJ Marwa","year":"2023","unstructured":"Marwa KJ, Kapesa A, Kamugisha E, Swedberg G. The influence of cytochrome P450 polymorphisms on pharmacokinetic profiles and treatment outcomes among malaria patients in Sub-Saharan Africa: a systematic review. Pharmgenomics Pers Med. 2023;16:449\u201361.","journal-title":"Pharmgenomics Pers Med"},{"issue":"1","key":"6181_CR11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103\u201341.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"6181_CR12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1389450118666170125144557","volume":"19","author":"P Manikandan","year":"2018","unstructured":"Manikandan P, Nagini S. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets. 2018;19(1):38\u201354.","journal-title":"Curr Drug Targets"},{"issue":"2","key":"6181_CR13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/03602530902843483","volume":"41","author":"SF Zhou","year":"2009","unstructured":"Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41(2):89\u2013295.","journal-title":"Drug Metab Rev"},{"issue":"6484","key":"6181_CR14","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay5012","volume":"367","author":"A Bergstr\u00f6m","year":"2020","unstructured":"Bergstr\u00f6m A, McCarthy SA, Hui R, Almarri MA, Ayub Q, Danecek P, et al. Insights into human genetic variation and population history from 929 diverse genomes. Science. 2020;367(6484):eaay5012.","journal-title":"Science"},{"key":"6181_CR15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/978-1-62703-321-3_21","volume-title":"Cytochrome P450 protocols","author":"SC Sim","year":"2013","unstructured":"Sim SC, Ingelman-Sundberg M. Update on allele nomenclature for human cytochromes P450 and the human cytochrome P450 allele (CYP-allele) nomenclature database. In: Phillips IR, Shephard EA, Ortiz de Montellano PR, editors. Cytochrome P450 protocols. Totowa: Humana Press; 2013. p. 251\u20139."},{"issue":"1","key":"6181_CR16","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/cts.12692","volume":"13","author":"KE Caudle","year":"2020","unstructured":"Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, Klein TE, et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci. 2020;13(1):116\u201324.","journal-title":"Clin Transl Sci"},{"issue":"8","key":"6181_CR17","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1124\/dmd.30.8.883","volume":"30","author":"JA Williams","year":"2002","unstructured":"Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002;30(8):883\u201391.","journal-title":"Drug Metab Dispos"},{"key":"6181_CR18","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2156-14-34","volume":"14","author":"RK Bains","year":"2013","unstructured":"Bains RK, Kovacevic M, Plaster CA, Tarekegn A, Bekele E, Bradman NN, et al. Molecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa. BMC Genet. 2013;14:34.","journal-title":"BMC Genet"},{"issue":"1","key":"6181_CR19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/mol.62.1.162","volume":"62","author":"YS Lin","year":"2002","unstructured":"Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol. 2002;62(1):162\u201372.","journal-title":"Mol Pharmacol"},{"issue":"1","key":"6181_CR20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","volume":"98","author":"KA Birdwell","year":"2015","unstructured":"Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015;98(1):19\u201324.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"6181_CR21","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1034\/j.1600-6143.2003.00077.x","volume":"3","author":"H Zheng","year":"2003","unstructured":"Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant. 2003;3(4):477\u201383.","journal-title":"Am J Transplant"},{"issue":"9","key":"6181_CR22","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jmoldx.2023.06.008","volume":"25","author":"VM Pratt","year":"2023","unstructured":"Pratt VM, Cavallari LH, Fulmer ML, Gaedigk A, Hachad H, Ji Y, et al. CYP3A4 and CYP3A5 Genotyping Recommendations: a Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase. J Mol Diagn. 2023;25(9):619\u201329.","journal-title":"J Mol Diagn"},{"issue":"4","key":"6181_CR23","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cpt.690","volume":"102","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 2017;102(4):688\u2013700.","journal-title":"Clin Pharmacol Ther"},{"issue":"5-6","key":"6181_CR24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41397-022-00288-2","volume":"22","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Lauschke VM. The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data. Pharmacogenomics J. 2022;22(5\u20136):284\u201393.","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"6181_CR25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/em.10199","volume":"42","author":"B Amirimani","year":"2003","unstructured":"Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF, Rebbeck TR. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen. 2003;42(4):299\u2013305.","journal-title":"Environ Mol Mutagen"},{"key":"6181_CR26","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2024.101029","volume":"57","author":"K Musyoka","year":"2024","unstructured":"Musyoka K, Chan CW, Guti\u00e9rrez Rico EM, Omondi P, Kijogi C, Okai T, et al. Genetic variation present in the CYP3A4 gene in Ni-Vanuatu and Kenyan populations in malaria endemicity. Drug Metab Pharmacokinet. 2024;57:101029.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"6","key":"6181_CR27","volume":"10","author":"WL Shi","year":"2015","unstructured":"Shi WL, Tang HL, Zhai SD. Effects of the CYP3A4*1B genetic polymorphism on the pharmacokinetics of tacrolimus in adult renal transplant recipients: a meta-analysis. PLoS ONE. 2015;10(6):e0127995.","journal-title":"PLoS ONE"},{"key":"6181_CR28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.gene.2018.04.043","volume":"664","author":"CE Wang","year":"2018","unstructured":"Wang CE, Lu KP, Chang Z, Guo ML, Qiao HL. Association of CYP3A4*1B genotype with Cyclosporin A pharmacokinetics in renal transplant recipients: a meta-analysis. Gene. 2018;664:44\u20139.","journal-title":"Gene"},{"key":"6181_CR29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fgene.2013.00017","volume":"4","author":"B Dr\u00f6gem\u00f6ller","year":"2013","unstructured":"Dr\u00f6gem\u00f6ller B, Plummer M, Korkie L, Agenbag G, Dunaiski A, Niehaus D, et al. Characterization of the genetic variation present in CYP3A4 in three South African populations. Front Genet. 2013;4:17.","journal-title":"Front Genet"},{"issue":"11","key":"6181_CR30","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","volume":"48","author":"SF Zhou","year":"2009","unstructured":"Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet. 2009;48(11):689\u2013723.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"6181_CR31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","volume":"98","author":"JK Hicks","year":"2015","unstructured":"Hicks JK, Bishop JR, Sangkuhl K, M\u00fcller DJ, Ji Y, Leckband SG, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015;98(2):127\u201334.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"6181_CR32","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1188\/13.ONF.547-548","volume":"40","author":"EC Smith","year":"2013","unstructured":"Smith EC. Understanding CYP2D6 and its role in tamoxifen metabolism. Oncol Nurs Forum. 2013;40(6):547\u20138.","journal-title":"Oncol Nurs Forum"},{"issue":"4","key":"6181_CR33","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2174\/138920008784220664","volume":"9","author":"SF Zhou","year":"2008","unstructured":"Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008;9(4):310\u201322.","journal-title":"Curr Drug Metab"},{"issue":"3","key":"6181_CR34","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/clpt.2010.279","volume":"89","author":"MV Relling","year":"2011","unstructured":"Relling MV, Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011;89(3):464\u20137.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"6181_CR35","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cpt.2350","volume":"110","author":"M Whirl-Carrillo","year":"2021","unstructured":"Whirl-Carrillo M, Huddart R, Gong L, Sangkuhl K, Thorn CF, Whaley R, et al. An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine. Clin Pharmacol Ther. 2021;110(3):563\u201372.","journal-title":"Clin Pharmacol Ther"},{"key":"6181_CR36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.addr.2017.06.013","volume":"118","author":"R Walther","year":"2017","unstructured":"Walther R, Rautio J, Zelikin AN. Prodrugs in medicinal chemistry and enzyme prodrug therapies. Adv Drug Deliv Rev. 2017;118:65\u201377.","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"6181_CR37","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1128\/AAC.47.12.3795-3798.2003","volume":"47","author":"K Silamut","year":"2003","unstructured":"Silamut K, Newton PN, Teja-Isavadharm P, Suputtamongkol Y, Siriyanonda D, Rasameesoraj M, et al. Artemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malaria. Antimicrob Agents Chemother. 2003;47(12):3795\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"6181_CR38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2165\/00003088-200847020-00002","volume":"47","author":"PI German","year":"2008","unstructured":"German PI, Aweeka FT. Clinical pharmacology of artemisinin-based combination therapies. Clin Pharmacokinet. 2008;47(2):91\u2013102.","journal-title":"Clin Pharmacokinet"},{"key":"6181_CR39","unstructured":"World Health Organisation. Guidelines for the treatment of malaria-3rd edition Geneva 2015 [cited 2025 01.10.2025]. Available from: https:\/\/iris.who.int\/handle\/10665\/162441."},{"issue":"3","key":"6181_CR40","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1472-8206.2007.00471.x","volume":"21","author":"S Asimus","year":"2007","unstructured":"Asimus S, Elsherbiny D, Hai TN, Jansson B, Huong NV, Petzold MG, et al. Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects. Fundam Clin Pharmacol. 2007;21(3):307\u201316.","journal-title":"Fundam Clin Pharmacol"},{"issue":"9","key":"6181_CR41","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1124\/dmd.112.045765","volume":"40","author":"J Xing","year":"2012","unstructured":"Xing J, Kirby BJ, Whittington D, Wan Y, Goodlett DR. Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes. Drug Metab Dispos. 2012;40(9):1757\u201364.","journal-title":"Drug Metab Dispos"},{"key":"6181_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-10-263","volume":"10","author":"CA Morris","year":"2011","unstructured":"Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J. 2011;10:263.","journal-title":"Malar J"},{"issue":"5","key":"6181_CR43","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/jac\/dks504","volume":"68","author":"GL Nixon","year":"2013","unstructured":"Nixon GL, Moss DM, Shone AE, Lalloo DG, Fisher N, O\u2019Neill PM, et al. Antimalarial pharmacology and therapeutics of atovaquone. J Antimicrob Chemother. 2013;68(5):977\u201385.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"6181_CR44","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1124\/dmd.31.6.748","volume":"31","author":"D Projean","year":"2003","unstructured":"Projean D, Baune B, Farinotti R, Flinois J-P, Beaune P, Taburet A-M, et al. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos. 2003;31(6):748\u201354.","journal-title":"Drug Metab Dispos"},{"key":"6181_CR45","unstructured":"Alfasigma S.p.A. Eurartesim, INN-piperaquine & INN-artenimol: EPAR- Product Information Bologna 2016 [updated 04.09.2025; cited 2025 01.10.2025]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/eurartesim#product-info."},{"issue":"2","key":"6181_CR46","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/jps.2600700230","volume":"70","author":"HJ Nelis","year":"1981","unstructured":"Nelis HJ, De Leenheer AP. Evidence for metabolic inertness of doxycycline. J Pharm Sci. 1981;70(2):226\u20138.","journal-title":"J Pharm Sci"},{"issue":"3","key":"6181_CR47","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1128\/AAC.01312-10","volume":"55","author":"RP Wong","year":"2011","unstructured":"Wong RP, Salman S, Ilett KF, Siba PM, Mueller I, Davis TM. Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome. Antimicrob Agents Chemother. 2011;55(3):1194\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"6181_CR48","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2165\/00003088-200140050-00003","volume":"40","author":"PT Giao","year":"2001","unstructured":"Giao PT, de Vries PJ. Pharmacokinetic interactions of antimalarial agents. Clin Pharmacokinet. 2001;40(5):343\u201373.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"6181_CR49","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1473-3099(07)70025-7","volume":"7","author":"SA Ward","year":"2007","unstructured":"Ward SA, Sevene EJP, Hastings IM, Nosten F, McGready R. Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis. 2007;7(2):136\u201344.","journal-title":"Lancet Infect Dis"},{"issue":"22","key":"6181_CR50","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0024-3205(00)00546-4","volume":"66","author":"F Fontaine","year":"2000","unstructured":"Fontaine F, de Sousa G, Burcham PC, Duch\u00eane P, Rahmani R. Role of cytochrome P450 3A in the metabolism of mefloquine in human and animal hepatocytes. Life Sci. 2000;66(22):2193\u2013212.","journal-title":"Life Sci"},{"key":"6181_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-259","volume":"11","author":"BS Pybus","year":"2012","unstructured":"Pybus BS, Sousa JC, Jin X, Ferguson JA, Christian RE, Barnhart R, et al. CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine. Malar J. 2012;11:259.","journal-title":"Malar J"},{"key":"6181_CR52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2016.03.011","volume":"161","author":"SR Marcsisin","year":"2016","unstructured":"Marcsisin SR, Reichard G, Pybus BS. Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: current state of the art. Pharmacol Ther. 2016;161:1\u201310.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"6181_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-018-2433-z","volume":"17","author":"B Avula","year":"2018","unstructured":"Avula B, Tekwani BL, Chaurasiya ND, Fasinu P, Dhammika Nanayakkara NP, Bhandara Herath HMT, et al. Metabolism of primaquine in normal human volunteers: investigation of phase I and phase II metabolites from plasma and urine using ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry. Malar J. 2018;17(1):294.","journal-title":"Malar J"},{"issue":"1","key":"6181_CR54","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.taap.2009.07.012","volume":"241","author":"S Ganesan","year":"2009","unstructured":"Ganesan S, Tekwani BL, Sahu R, Tripathi LM, Walker LA. Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes. Toxicol Appl Pharmacol. 2009;241(1):14\u201322.","journal-title":"Toxicol Appl Pharmacol"},{"key":"6181_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-12-212","volume":"12","author":"BS Pybus","year":"2013","unstructured":"Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, et al. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar J. 2013;12:212.","journal-title":"Malar J"},{"issue":"4","key":"6181_CR56","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1086\/314683","volume":"179","author":"A Kaneko","year":"1999","unstructured":"Kaneko A, Bergqvist Y, Takechi M, Kalkoa M, Kaneko O, Kobayakawa T, et al. Intrinsic efficacy of proguanil against falciparum and vivax malaria independent of the metabolite cycloguanil. J Infect Dis. 1999;179(4):974\u20139.","journal-title":"J Infect Dis"},{"issue":"6","key":"6181_CR57","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1128\/AAC.43.6.1334","volume":"43","author":"IK Srivastava","year":"1999","unstructured":"Srivastava IK, Vaidya AB. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother. 1999;43(6):1334\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"6181_CR58","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/BF03190031","volume":"24","author":"XJ Zhao","year":"1999","unstructured":"Zhao XJ, Ishizaki T. A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition. Eur J Drug Metab Pharmacokinet. 1999;24(3):272\u20138.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"6181_CR59","doi-asserted-by":"crossref","DOI":"10.3390\/ph12030115","volume":"12","author":"A Mayence","year":"2018","unstructured":"Mayence A, Vanden Eynde JJ. Tafenoquine: a 2018 novel FDA-approved prodrug for the radical cure of Plasmodium vivax malaria and prophylaxis of malaria. Pharmaceuticals (Basel). 2018;12(3):115.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"6181_CR60","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00711-18","volume":"62","author":"N Thakkar","year":"2018","unstructured":"Thakkar N, Green JA, Koh G, Duparc S, Tenero D, Goyal N. Population pharmacokinetics of tafenoquine, a novel antimalarial. Antimicrob Agents Chemother. 2018;62(11):e00711-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"6181_CR61","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01014-23","volume":"67","author":"S Dowd","year":"2023","unstructured":"Dowd S, Chen N, Gatton ML, Edstein MD, Cheng Q. Cytochrome P450 2D6 profiles and anti-relapse efficacy of tafenoquine against Plasmodium vivax in Australian Defence Force personnel. Antimicrob Agents Chemother. 2023;67(12):e0101423.","journal-title":"Antimicrob Agents Chemother"},{"key":"6181_CR62","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1475-2875-13-2","volume":"13","author":"SR Marcsisin","year":"2014","unstructured":"Marcsisin SR, Sousa JC, Reichard GA, Caridha D, Qiang Z, Roncal N, et al. Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds. Malar J. 2014;13:2.","journal-title":"Malar J"},{"key":"6181_CR63","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12936-016-1145-5","volume":"15","author":"PL St Jean","year":"2016","unstructured":"St Jean PL, Xue Z, Carter N, Koh GC, Duparc S, Taylor M, et al. Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial. Malar J. 2016;15:97.","journal-title":"Malar J"},{"key":"6181_CR64","doi-asserted-by":"publisher","unstructured":"World Health Organisation. WHO guidelines for malaria-30 November 2024 Geneva 2024 [updated 30.11.2024; cited 2025 01.10.2025]. Available from: https:\/\/doi.org\/10.2471\/B09146.","DOI":"10.2471\/B09146"},{"issue":"1","key":"6181_CR65","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbrc.2005.09.020","volume":"338","author":"C Rodr\u00edguez-Antona","year":"2005","unstructured":"Rodr\u00edguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun. 2005;338(1):299\u2013305.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"6181_CR66","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/01.fpc.0000230411.89973.1b","volume":"16","author":"RA Mirghani","year":"2006","unstructured":"Mirghani RA, Sayi J, Aklillu E, Allqvist A, Jande M, Wennerholm A, et al. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet Genomics. 2006;16(9):637\u201345.","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"6181_CR67","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/FPC.0b013e3282f50ee9","volume":"18","author":"U Diczfalusy","year":"2008","unstructured":"Diczfalusy U, Miura J, Roh HK, Mirghani RA, Sayi J, Larsson H, et al. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics. 2008;18(3):201\u20138.","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"6181_CR68","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/FTD.0b013e3181da79d6","volume":"32","author":"JK Mukonzo","year":"2010","unstructured":"Mukonzo JK, Waako P, Ogwal-Okeng J, Gustafsson LL, Aklillu E. Genetic variations in ABCB1 and CYP3A5 as well as sex influence quinine disposition among Ugandans. Ther Drug Monit. 2010;32(3):346\u201352.","journal-title":"Ther Drug Monit"},{"key":"6181_CR69","volume":"10","author":"XY Zhou","year":"2019","unstructured":"Zhou XY, Hu XX, Wang CC, Lu XR, Chen Z, Liu Q, et al. Enzymatic activities of CYP3A4 allelic variants on quinine 3-hydroxylation in vitro. Front Pharmacol. 2019;10:591.","journal-title":"Front Pharmacol"},{"issue":"22","key":"6181_CR70","first-page":"1922","volume":"335","author":"S Anderer","year":"2026","unstructured":"Anderer S. WHO announces first malaria drug for infants and new rapid diagnostic tests. JAMA. 2026;335(22):1922.","journal-title":"JAMA"},{"issue":"2","key":"6181_CR71","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1128\/AAC.01700-12","volume":"57","author":"EM Staehli Hodel","year":"2013","unstructured":"Staehli Hodel EM, Csajka C, Ariey F, Guidi M, Kabanywanyi AM, Duong S, et al. Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania. Antimicrob Agents Chemother. 2013;57(2):950\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"6181_CR72","doi-asserted-by":"crossref","unstructured":"Kiaco K, Rodrigues AS, do Ros\u00e1rio V, Gil JP, Lopes D. The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome. Malar J. 2017;16(1):383.","DOI":"10.1186\/s12936-017-2006-6"},{"key":"6181_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-420","volume":"13","author":"KJ Marwa","year":"2014","unstructured":"Marwa KJ, Schmidt T, Sj\u00f6gren M, Minzi OMS, Kamugisha E, Swedberg G. Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations. Malar J. 2014;13:420.","journal-title":"Malar J"},{"issue":"1","key":"6181_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-024-04930-1","volume":"23","author":"NE Thomford","year":"2024","unstructured":"Thomford NE, Kellermann T, Biney RP, Dixon C, Nyarko SB, Ateko RO, et al. Therapeutic efficacy of generic artemether-lumefantrine in the treatment of uncomplicated malaria in Ghana: assessing anti-malarial efficacy amidst pharmacogenetic variations. Malar J. 2024;23(1):125.","journal-title":"Malar J"},{"key":"6181_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-017-1914-9","volume":"16","author":"RF Mutagonda","year":"2017","unstructured":"Mutagonda RF, Kamuhabwa AAR, Minzi OMS, Massawe SN, Asghar M, Homann MV, et al. Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women. Malar J. 2017;16:267.","journal-title":"Malar J"},{"issue":"12","key":"6181_CR76","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1124\/dmd.119.088062","volume":"47","author":"RF Mutagonda","year":"2019","unstructured":"Mutagonda RF, Minzi OMS, Massawe SN, Asghar M, F\u00e4rnert A, Kamuhabwa AAR, et al. Pregnancy and CYP3A5 genotype affect day 7 plasma lumefantrine concentrations. Drug Metab Dispos. 2019;47(12):1415\u201324.","journal-title":"Drug Metab Dispos"},{"key":"6181_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0695-2","volume":"14","author":"BA Maganda","year":"2015","unstructured":"Maganda BA, Ngaimisi E, Kamuhabwa AA, Aklillu E, Minzi OM. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Malar J. 2015;14:179.","journal-title":"Malar J"},{"issue":"1","key":"6181_CR78","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/tpj.2015.37","volume":"16","author":"BA Maganda","year":"2016","unstructured":"Maganda BA, Minzi OM, Ngaimisi E, Kamuhabwa AA, Aklillu E. CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients. Pharmacogenomics J. 2016;16(1):88\u201395.","journal-title":"Pharmacogenomics J"},{"issue":"18","key":"6181_CR79","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.2217\/pgs-2020-0081","volume":"21","author":"AJ Adegbola","year":"2020","unstructured":"Adegbola AJ, Soyinka JO, Bolaji OO. Effect of CYP3A5*3 genotypes on lumefantrine plasma concentrations among malaria-HIV-infected women. Pharmacogenomics. 2020;21(18):1289\u201397.","journal-title":"Pharmacogenomics"},{"issue":"4","key":"6181_CR80","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s13318-023-00833-9","volume":"48","author":"S Bettonte","year":"2023","unstructured":"Bettonte S, Berton M, Stader F, Battegay M, Marzolini C. Management of Drug Interactions with Inducers: onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates. Eur J Drug Metab Pharmacokinet. 2023;48(4):353\u201362.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"6181_CR81","unstructured":"World Health Organisation. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach Geneva 2021 [updated 16.07.2021; cited 2025 01.10.2025]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240031593."},{"key":"6181_CR82","unstructured":"Centers for Disease Control and Prevention, HIV Medicine Association of the Infectious Diseases Society of America; Pediatric Infectious Diseases Society, HHS Panel on Treatment of HIV during Pregnancy and Prevention of Perinatal Transmission\u2014a Working Group of the Office of AIDS Research Advisory Council (OARAC). Recommendations for the Use of Antiretroviral Drugs during Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States Rockville (MD): US Department of Health and Human Services; 2025 [updated 12.06.2025; cited 2025 01.10.2025]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK586310\/."},{"issue":"1","key":"6181_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-025-00787-9","volume":"22","author":"NE Thomford","year":"2025","unstructured":"Thomford NE, Kellermann T, Twum JA, Anyimadu J, Dixon C, Sappor D, et al. Drug-drug interaction between dolutegravir and artemether-lumefantrine in HIV and malaria mono- and co-infections: a pharmacogenetic analysis from Ghana. AIDS Res Ther. 2025;22(1):85.","journal-title":"AIDS Res Ther"},{"issue":"6","key":"6181_CR84","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1097\/QAD.0b013e32835cae3b","volume":"27","author":"M Lamorde","year":"2013","unstructured":"Lamorde M, Byakika-Kibwika P, Mayito J, Nabukeera L, Ryan M, Hanpithakpong W, et al. Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment. AIDS. 2013;27(6):961\u20135.","journal-title":"AIDS"},{"key":"6181_CR85","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejps.2017.05.043","volume":"106","author":"O Olafuyi","year":"2017","unstructured":"Olafuyi O, Coleman M, Badhan RKS. Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: a case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin. Eur J Pharm Sci. 2017;106:20\u201333.","journal-title":"Eur J Pharm Sci"},{"key":"6181_CR86","volume":"181","author":"X Zhang","year":"2023","unstructured":"Zhang X, Li Q, Zhou Q, Li Y, Li J, Jin L, et al. Determine the enzymatic kinetic characteristics of CYP3A4 variants utilizing artemether-lumefantrine. Food Chem Toxicol. 2023;181:114065.","journal-title":"Food Chem Toxicol"},{"issue":"16","key":"6181_CR87","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa021592","volume":"349","author":"E Schwartz","year":"2003","unstructured":"Schwartz E, Parise M, Kozarsky P, Cetron M. Delayed onset of malaria\u2013implications for chemoprophylaxis in travelers. N Engl J Med. 2003;349(16):1510\u20136.","journal-title":"N Engl J Med"},{"issue":"10","key":"6181_CR88","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/trstmh\/trz052","volume":"113","author":"C Rodrigo","year":"2019","unstructured":"Rodrigo C, Rajapakse S, Fernando SD. Tafenoquine for primary and terminal prophylaxis of malaria in apparently healthy people: a systematic review. Trans R Soc Trop Med Hyg. 2019;113(10):579\u201386.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"3","key":"6181_CR89","doi-asserted-by":"crossref","first-page":"402","DOI":"10.4269\/ajtmh.2006.75.402","volume":"75","author":"DR Hill","year":"2006","unstructured":"Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg. 2006;75(3):402\u201315.","journal-title":"Am J Trop Med Hyg"},{"issue":"14","key":"6181_CR90","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1056\/NEJMc1301936","volume":"369","author":"JW Bennett","year":"2013","unstructured":"Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med. 2013;369(14):1381\u20132.","journal-title":"N Engl J Med"},{"issue":"4","key":"6181_CR91","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.1449","volume":"1","author":"JK Baird","year":"2018","unstructured":"Baird JK, Louisa M, Noviyanti R, Ekawati L, Elyazar I, Subekti D, et al. Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype with Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria. JAMA Netw Open. 2018;1(4):e181449.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"6181_CR92","volume":"64","author":"ACR Silvino","year":"2020","unstructured":"Silvino ACR, Kano FS, Costa MA, Fontes CJF, Soares IS, de Brito CFA, et al. Novel insights into Plasmodium vivax therapeutic failure: CYP2D6 activity and time of exposure to malaria modulate the risk of recurrence. Antimicrob Agents Chemother. 2020;64(5):e02056-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"6181_CR93","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s12936-021-03869-x","volume":"20","author":"A de Pina-Costa","year":"2021","unstructured":"de Pina-Costa A, Silvino ACR, Dos Santos EM, Pedro RS, Moreira J, Umana GL, et al. Increased primaquine total dose prevents Plasmodium vivax relapses in patients with impaired CYP2D6 activity: report of three cases. Malar J. 2021;20(1):341.","journal-title":"Malar J"},{"issue":"2","key":"6181_CR94","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/cid\/ciae482","volume":"81","author":"W Zeng","year":"2025","unstructured":"Zeng W, Liu H, Malla P, Zhao Y, Menezes L, Cao Y, et al. Efficacy of Primaquine for the Radical Cure of Plasmodium vivax Malaria in Northeast Myanmar and the Impact of Cytochrome P450 2D6 Genotypes. Clin Infect Dis. 2025;81(2):379\u201386.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"6181_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-94679-7","volume":"15","author":"GS da Silva","year":"2025","unstructured":"da Silva GS, Fontenelle FA, Carvalho AO, Mac\u00eado MM, Morais MC, Abreu Netto RL, et al. Impact of CYP2D6, MAOA, and UGT2B7 genetic variants on recurrence of Plasmodium vivax in the Brazilian Amazon. Sci Rep. 2025;15(1):15330.","journal-title":"Sci Rep"},{"issue":"3","key":"6181_CR96","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2025.117013","volume":"113","author":"V Sierra-Cifuentes","year":"2025","unstructured":"Sierra-Cifuentes V, Zuluaga-Id\u00e1rraga L, Aguirre-Acevedo D, Silva de Barros Pu\u00e7a MC, Nobrega de Sousa T, Lopera-Mesa TM. Polymorphisms of the CYP2D6 gene and its relationship with Plasmodium vivax relapses after chloroquine-primaquine treatment in Turbo, Colombia. Diagn Microbiol Infect Dis. 2025;113(3):117013.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"6","key":"6181_CR97","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1128\/AAC.02794-13","volume":"58","author":"S Pukrittayakamee","year":"2014","unstructured":"Pukrittayakamee S, Tarning J, Jittamala P, Charunwatthana P, Lawpoolsri S, Lee SJ, et al. Pharmacokinetic interactions between primaquine and chloroquine. Antimicrob Agents Chemother. 2014;58(6):3354\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"6181_CR98","doi-asserted-by":"crossref","first-page":"7340","DOI":"10.1128\/AAC.03704-14","volume":"58","author":"B Hanboonkunupakarn","year":"2014","unstructured":"Hanboonkunupakarn B, Ashley EA, Jittamala P, Tarning J, Pukrittayakamee S, Hanpithakpong W, et al. Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult Thai subjects. Antimicrob Agents Chemother. 2014;58(12):7340\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"14","key":"6181_CR99","first-page":"1127","volume":"21","author":"SP Rendic","year":"2020","unstructured":"Rendic SP, Guengerich FP. Metabolism and interactions of chloroquine and hydroxychloroquine with human cytochrome P450 enzymes and drug transporters. Curr Drug Metab. 2020;21(14):1127\u201335.","journal-title":"Curr Drug Metab"},{"issue":"4","key":"6181_CR100","volume":"26","author":"CS Chu","year":"2019","unstructured":"Chu CS, Freedman DO. Tafenoquine and G6PD: a primer for clinicians. J Travel Med. 2019;26(4):taz023.","journal-title":"J Travel Med"},{"issue":"46","key":"6181_CR101","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.15585\/mmwr.mm6846a4","volume":"68","author":"J Haston","year":"2019","unstructured":"Haston J, Hwang J, Tan K. Guidance for using tafenoquine for prevention and antirelapse therapy for malaria\u2014United States, 2019. MMWR Morb Mortal Wkly Rep. 2019;68(46):1062\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"6181_CR102","volume":"70","author":"VKC Godinho","year":"2026","unstructured":"Godinho VKC, Mwangi VI, Morais MC, Lopes APB, Alves J, Brito MAM, et al. Differential impact of Tafenoquine and Primaquine on Plasmodium vivax recurrence: the role of CYP2D6 variants. Antimicrob Agents Chemother. 2026;70(6):e01797-25.","journal-title":"Antimicrob Agents Chemother"},{"key":"6181_CR103","doi-asserted-by":"crossref","unstructured":"WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK\/PD Study Group. Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data. BMC Med. 2015;13:227.","DOI":"10.1186\/s12916-015-0456-7"},{"issue":"11","key":"6181_CR104","doi-asserted-by":"crossref","DOI":"10.1038\/psp.2013.59","volume":"2","author":"F Kloprogge","year":"2013","unstructured":"Kloprogge F, Piola P, Dhorda M, Muwanga S, Turyakira E, Apinan S, et al. Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda. CPT Pharmacometrics Syst Pharmacol. 2013;2(11):e83.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"12","key":"6181_CR105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050253","volume":"5","author":"R McGready","year":"2008","unstructured":"McGready R, Tan SO, Ashley EA, Pimanpanarak M, Viladpai-Nguen J, Phaiphun L, et al. A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated Plasmodium falciparum treatment in pregnancy. PLoS Med. 2008;5(12):e253.","journal-title":"PLoS Med"},{"issue":"3","key":"6181_CR106","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bcp.70318","volume":"92","author":"E Juma","year":"2026","unstructured":"Juma E, Ding J, Ongas M, Koskei N, Onyango K, Oloo F, et al. Population pharmacokinetics of lumefantrine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Western Kenya. Br J Clin Pharmacol. 2026;92(3):911\u201321.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"6181_CR107","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002579","volume":"15","author":"F Kloprogge","year":"2018","unstructured":"Kloprogge F, Workman L, Borrmann S, T\u00e9k\u00e9t\u00e9 M, Lef\u00e8vre G, Hamed K, et al. Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: a pharmacokinetic-pharmacodynamic meta-analysis. PLoS Med. 2018;15(6):e1002579.","journal-title":"PLoS Med"},{"issue":"6","key":"6181_CR108","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/bcp.16048","volume":"91","author":"M Ingelman-Sundberg","year":"2025","unstructured":"Ingelman-Sundberg M, Molden E. Therapeutic drug monitoring, liquid biopsies or pharmacogenomics for prediction of human drug metabolism and response. Br J Clin Pharmacol. 2025;91(6):1569\u201379.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"6181_CR109","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.pt.2008.01.006","volume":"24","author":"NJ White","year":"2008","unstructured":"White NJ, Stepniewska K, Barnes K, Price RN, Simpson J. Simplified antimalarial therapeutic monitoring: Using the day-7 drug level? Trends Parasitol. 2008;24(4):159\u201363.","journal-title":"Trends Parasitol"},{"issue":"1","key":"6181_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-020-3150-y","volume":"19","author":"M Kilonzi","year":"2020","unstructured":"Kilonzi M, Minzi O, Mutagonda R, Baraka V, Sasi P, Aklillu E, et al. Usefulness of day 7 lumefantrine plasma concentration as a predictor of malaria treatment outcome in under-fives children treated with artemether-lumefantrine in Tanzania. Malar J. 2020;19(1):66.","journal-title":"Malar J"},{"issue":"6","key":"6181_CR111","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.4269\/ajtmh.20-0852","volume":"103","author":"MM Ippolito","year":"2020","unstructured":"Ippolito MM, Pringle JC, Siame M, Katowa B, Aydemir O, Oluoch PO, et al. Therapeutic efficacy of artemether-lumefantrine for uncomplicated falciparum malaria in Northern Zambia. Am J Trop Med Hyg. 2020;103(6):2224\u201332.","journal-title":"Am J Trop Med Hyg"},{"key":"6181_CR112","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-8-204","volume":"8","author":"DJ Bell","year":"2009","unstructured":"Bell DJ, Wootton D, Mukaka M, Montgomery J, Kayange N, Chimpeni P, et al. Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. Malar J. 2009;8:204.","journal-title":"Malar J"},{"key":"6181_CR113","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijid.2022.08.020","volume":"123","author":"KJ Marwa","year":"2022","unstructured":"Marwa KJ, Liwa AC, Konje ET, Mwita S, Kamugisha E, Swedberg G. Lumefantrine plasma concentrations in uncontrolled conditions among patients treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Mwanza, Tanzania. Int J Infect Dis. 2022;123:192\u20139.","journal-title":"Int J Infect Dis"},{"issue":"10","key":"6181_CR114","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2165\/00003088-200544100-00001","volume":"44","author":"GD Anderson","year":"2005","unstructured":"Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet. 2005;44(10):989\u20131008.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"6181_CR115","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1124\/dmd.112.050245","volume":"41","author":"N Isoherranen","year":"2013","unstructured":"Isoherranen N, Thummel KE. Drug metabolism and transport during pregnancy: How does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Drug Metab Dispos. 2013;41(2):256\u201362.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"6181_CR116","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s002280050323","volume":"52","author":"S Pukrittayakamee","year":"1997","unstructured":"Pukrittayakamee S, Looareesuwan S, Keeratithakul D, Davis TM, Teja-Isavadharm P, Nagachinta B, et al. A study of the factors affecting the metabolic clearance of quinine in malaria. Eur J Clin Pharmacol. 1997;52(6):487\u201393.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"6181_CR117","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-019-2860-5","volume":"18","author":"SM Mimche","year":"2019","unstructured":"Mimche SM, Lee CM, Liu KH, Mimche PN, Harvey RD, Murphy TJ, et al. A non-lethal malarial infection results in reduced drug metabolizing enzyme expression and drug clearance in mice. Malar J. 2019;18(1):234.","journal-title":"Malar J"},{"issue":"1","key":"6181_CR118","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-016-1327-1","volume":"15","author":"RF Mutagonda","year":"2016","unstructured":"Mutagonda RF, Kamuhabwa AA, Minzi OM, Massawe SN, Maganda BA, Aklillu E. Malaria prevalence, severity and treatment outcome in relation to day 7 lumefantrine plasma concentration in pregnant women. Malar J. 2016;15(1):278.","journal-title":"Malar J"},{"issue":"4","key":"6181_CR119","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/cpt.2192","volume":"109","author":"P Hazenberg","year":"2021","unstructured":"Hazenberg P, Navaratnam K, Busuulwa P, Waitt C. Anti-infective dosing in special populations: pregnancy. Clin Pharmacol Ther. 2021;109(4):977\u201386.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"6181_CR120","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02394-19","volume":"64","author":"J Francis","year":"2020","unstructured":"Francis J, Barnes KI, Workman L, Kredo T, Vestergaard LS, Hoglund RM, et al. An individual participant data population pharmacokinetic meta-analysis of drug-drug interactions between lumefantrine and commonly used antiretroviral treatment. Antimicrob Agents Chemother. 2020;64(5):e02394-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"6181_CR121","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1093\/jac\/dkab022","volume":"76","author":"AN Kawuma","year":"2021","unstructured":"Kawuma AN, Walimbwa SI, Pillai GC, Khoo S, Lamorde M, Wasmann RE, et al. Dolutegravir pharmacokinetics during co-administration with either artemether\/lumefantrine or artesunate\/amodiaquine. J Antimicrob Chemother. 2021;76(5):1269\u201372.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"6181_CR122","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01310-18","volume":"63","author":"SI Walimbwa","year":"2019","unstructured":"Walimbwa SI, Lamorde M, Waitt C, Kaboggoza J, Else L, Byakika-Kibwika P, et al. Drug interactions between dolutegravir and artemether-lumefantrine or artesunate-amodiaquine. Antimicrob Agents Chemother. 2019;63(2):e01310-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"6181_CR123","doi-asserted-by":"crossref","DOI":"10.3390\/tropicalmed7080152","volume":"7","author":"A Figueroa-Romero","year":"2022","unstructured":"Figueroa-Romero A, Pons-Duran C, Gonzalez R. Drugs for intermittent preventive treatment of malaria in pregnancy: current knowledge and way forward. Trop Med Infect Dis. 2022;7(8):152.","journal-title":"Trop Med Infect Dis"},{"issue":"7","key":"6181_CR124","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1128\/AAC.00343-15","volume":"59","author":"C Vuong","year":"2015","unstructured":"Vuong C, Xie LH, Potter BM, Zhang J, Zhang P, Duan D, et al. Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics. Antimicrob Agents Chemother. 2015;59(7):3864\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"6181_CR125","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1473-3099(24)00074-4","volume":"24","author":"M Brito","year":"2024","unstructured":"Brito M, Rufatto R, Brito-Sousa JD, Murta F, Sampaio V, Balieiro P, et al. Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study. Lancet Infect Dis. 2024;24(6):629\u201338.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"6181_CR126","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004255","volume":"21","author":"DJ Price","year":"2024","unstructured":"Price DJ, Nekkab N, Monteiro WM, Villela DAM, Simpson JA, Lacerda MVG, et al. Tafenoquine following G6PD screening versus primaquine for the treatment of vivax malaria in Brazil: a cost-effectiveness analysis using a transmission model. PLoS Med. 2024;21(1):e1004255.","journal-title":"PLoS Med"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-06181-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-026-06181-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-06181-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:21:19Z","timestamp":1792160479000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-026-06181-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":126,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6181"],"URL":"https:\/\/doi.org\/10.1186\/s12936-026-06181-8","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"21 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"368"}}